/content/dam/asset-migration/headshots/uk-doctor-headshots/UK_Oncology_Headshot_GA_Dr Shivan Sivakumar.jpg

Dr Shivan Sivakumar

Dr Shivan Sivakumar
BMedSci, MBBS, PhD, MRCP. Honorary consultant in Medical Oncology, Clinical development fellow in medical oncology, University of Oxford

Languages spoken


Expert in

Medical Oncology 




Peters Way, Sandy Lane West, Oxford, OX4 6LB

51.7239071200697, -1.2145938932540707
+44 (0)1865 237 700
mediahawkNumber3680 mhMobile

Dr Shivan Sivakumar is a medical oncologist with a particular interest in cancers of the pancreas, biliary tree and liver. His predominant employment is with the University of Oxford and he runs a clinical trials programme in all three cancer groups. Dr Sivakumar also runs a translational research programme in pancreatic cancer at the university as there is a high need for novel therapeutics and diagnostics for this cancer.

Clinical interests

  • Hepatopancreatobiliary oncology
  • Drug development in gastrointestinal oncology
  • Pancreatic cancer research

Professional memberships

  • Membership of Royal College of Physicians
  • ESMO
  • ASCO
  • ESMO


Awards received

  • NCRI future of research award 2020


  • Sivakumar, S., Abu-Shah, E., Ahern, D., Arbe-Barnes, E.H., Mangal, N., Reddy, S., Rendek, A., Easton, A., Kurz, E., Silva, M. and Heij, L.R., 2020. Immune responses in pancreatic cancer may be restricted by prevalence of activated regulatory T-cells, dysfunctional CD8+ T-cells, and senescent T-cells.bioRxiv.
  • Lee, L.Y., Cazier, J.B., Starkey, T., Turnbull, C.D., Team, U.C.C.M.P., Kerr, R. and Middleton, G., 2020. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study.The Lancet.
  • De Santiago, I., Yau, C., Heij, L., Middleton, M.R., Markowetz, F., Grabsch, H.I., Dustin, M.L. and Sivakumar, S., 2019. Immunophenotypes of pancreatic ductal adenocarcinoma: Meta‐analysis of transcriptional subtypes.International journal of cancer145(4), pp.1125-1137.
  • Sivakumar, S., de Santiago, I., Chlon, L. and Markowetz, F., 2017. Master regulators of oncogenic KRAS response in pancreatic cancer: an integrative network biology analysis.PLoS medicine14(1), p.e1002223.
  • Grabsch, H., Sivakumar, S., Gray, S., Gabbert, H.E. and Müller, W., 2010. HER2 expression in gastric cancer: rare, heterogeneous and of no prognostic value–conclusions from 924 cases of two independent series.Analytical Cellular Pathology32(1-2), pp.57-65.